EBIT: Income before interest and taxes.
4D Molecular Therapeutics, Inc. (FDMT) had EBIT of $-73.62M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$3.05M |
|
$-68.76M |
|
-- |
|
$3.05M |
|
$76.67M |
|
$-73.62M |
|
$4.86M |
|
$-68.76M |
|
$-68.76M |
|
$-68.76M |
|
$-68.76M |
|
$-68.76M |
|
$-68.76M |
|
|
EBIT |
$-73.62M |
$-73.48M |
|
68.06M |
|
68.06M |
|
$-1.01 |
|
$-1.01 |
|
| Balance Sheet Financials | |
$405.36M |
|
$13.59M |
|
$107.54M |
|
$512.90M |
|
$43.40M |
|
-- |
|
$17.66M |
|
$61.07M |
|
$451.84M |
|
$451.84M |
|
$451.84M |
|
52.27M |
|
| Cash Flow Statement Financials | |
$-68.12M |
|
$68.89M |
|
$11.48M |
|
$60.24M |
|
$72.49M |
|
$12.25M |
|
$4.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-2416.15% |
|
-2416.15% |
|
-- |
|
-2256.65% |
|
-2256.65% |
|
$-68.11M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-15.22% |
|
-15.22% |
|
-13.41% |
|
-15.22% |
|
$8.64 |
|
$-1.00 |
|
$-1.00 |
|